Total Payments
$36,884
2024 Payments
$3,985
Companies
8
Transactions
54
Medicare Patients
1,107
Medicare Billing
$252,014
Payment Breakdown by Category
Consulting$26,084 (70.7%)
Research$8,198 (22.2%)
Travel$1,747 (4.7%)
Food & Beverage$560.53 (1.5%)
Other$272.25 (0.7%)
Education$22.36 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $26,084 | 8 | 70.7% |
| Unspecified | $8,198 | 34 | 22.2% |
| Travel and Lodging | $1,747 | 6 | 4.7% |
| Food and Beverage | $560.53 | 3 | 1.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $272.25 | 2 | 0.7% |
| Education | $22.36 | 1 | 0.1% |
Payments by Type
General
$28,686
20 transactions
Research
$8,198
34 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $10,214 | 5 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,856 | 6 | $0 (2022) |
| Astellas Pharma Global Development | $8,198 | 34 | $0 (2021) |
| Millennium Pharmaceuticals, Inc. | $5,325 | 5 | $0 (2017) |
| PFIZER INC. | $3,000 | 1 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $174.42 | 1 | $0 (2024) |
| TAIHO ONCOLOGY, INC. | $97.83 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $19.38 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,985 | 4 | Novartis Pharmaceuticals Corporation ($3,713) |
| 2023 | $1,856 | 1 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,856) |
| 2022 | $2,047 | 2 | Novartis Pharmaceuticals Corporation ($2,025) |
| 2021 | $2,815 | 3 | Novartis Pharmaceuticals Corporation ($2,620) |
| 2020 | $3,849 | 23 | Astellas Pharma Global Development ($3,849) |
| 2019 | $13,988 | 14 | Takeda Pharmaceuticals U.S.A., Inc. ($9,834) |
| 2018 | $3,000 | 1 | PFIZER INC. ($3,000) |
| 2017 | $5,344 | 6 | Millennium Pharmaceuticals, Inc. ($5,325) |
All Payment Transactions
54 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/30/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $174.42 | General |
| 09/30/2024 | TAIHO ONCOLOGY, INC. | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $97.83 | General |
| 06/28/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 06/07/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,362.50 | General |
| 10/19/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,856.25 | General |
| 11/30/2022 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $22.36 | General |
| 09/23/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,620.00 | General |
| 07/26/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $94.58 | Research |
| Study: A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. • Category: ONCOLOGY | ||||||
| 01/20/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $100.00 | Research |
| Study: A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. • Category: ONCOLOGY | ||||||
| 10/19/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $100.00 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 10/19/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $70.83 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 10/19/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $70.83 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 09/18/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $449.58 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 09/18/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $70.83 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 07/09/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $100.00 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 07/09/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $100.00 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 06/15/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $23.75 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 06/15/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $22.35 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 05/20/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $427.21 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 05/20/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $70.83 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 05/20/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $53.13 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 04/21/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $427.71 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 03/17/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $151.66 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 03/17/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $140.00 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation | Astellas Pharma Global Development | $4,154 | 9 |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | Astellas Pharma Global Development | $3,849 | 23 |
| A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. | Astellas Pharma Global Development | $194.58 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 286 | 605 | $346,955 | $59,827 |
| 2022 | 6 | 277 | 649 | $389,365 | $66,315 |
| 2021 | 8 | 338 | 794 | $463,020 | $83,592 |
| 2020 | 6 | 206 | 502 | $262,060 | $42,279 |
Total Patients
1,107
Total Services
2,550
Medicare Billing
$252,014
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 38 | 210 | $109,200 | $22,430 | 20.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 61 | 118 | $86,140 | $14,355 | 16.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 81 | 136 | $74,120 | $10,803 | 14.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 36 | 36 | $37,620 | $5,660 | 15.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 37 | $13,320 | $2,619 | 19.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 33 | $12,375 | $1,778 | 14.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 16 | 16 | $10,000 | $1,653 | 16.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 17 | 19 | $4,180 | $529.15 | 12.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 43 | 263 | $138,075 | $24,572 | 17.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 57 | 141 | $104,340 | $18,578 | 17.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 90 | 150 | $81,750 | $12,822 | 15.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 49 | 49 | $51,205 | $8,370 | 16.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 25 | $9,375 | $1,351 | 14.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 18 | 21 | $4,620 | $622.84 | 13.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 64 | 359 | $181,295 | $34,249 | 18.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 71 | 172 | $123,840 | $23,187 | 18.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 94 | 147 | $80,115 | $12,929 | 16.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 39 | 39 | $40,755 | $6,790 | 16.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 14 | $13,930 | $2,594 | 18.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 26 | 27 | $9,585 | $1,810 | 18.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 19 | 23 | $8,625 | $1,207 | 14.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 11 | 13 | $4,875 | $827.71 | 17.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 34 | 194 | $96,030 | $18,770 | 19.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 62 | 179 | $93,080 | $12,996 | 14.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 23 | 24 | $24,520 | $3,798 | 15.5% |
About Dr. Ellin Berman, MD
Dr. Ellin Berman, MD is a Hematology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083685861.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ellin Berman, MD has received a total of $36,884 in payments from pharmaceutical and medical device companies, with $3,985 received in 2024. These payments were reported across 54 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($26,084).
As a Medicare-enrolled provider, Berman has provided services to 1,107 Medicare beneficiaries, totaling 2,550 services with total Medicare billing of $252,014. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Location New York, NY
- Active Since 01/30/2006
- Last Updated 04/07/2015
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1083685861
Products in Payments
- ICLUSIG (Drug) $9,834
- XOSPATA (Drug) $8,198
- SCEMBLIX (Drug) $3,375
- BAVENCIO (Drug) $3,000
- DIFICID (Drug) $19.38
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in New York
Dr. Barry Coller, M.d, M.D
Hematology — Payments: $10.2M
Hematology $10.2M
Dr. Dan Douer, M.d, M.D
Hematology — Payments: $665,161
Hematology $665,161
Louis Aledort, Md, MD
Hematology — Payments: $377,491
Hematology $377,491
Michael Mauro, Md, MD
Hematology — Payments: $374,307
Hematology $374,307
Faith Davies, Md, MD
Hematology — Payments: $373,421
Hematology $373,421
Ann Jakubowski, Md, MD
Hematology — Payments: $92,726
Hematology $92,726